Aytu BioScience logo
Aytu BioScience AYTU
$ 2.64 -0.19%

Quarterly report 2025-Q4
added 02-03-2026

report update icon

Aytu BioScience Cash Flow 2011-2026 | AYTU

Annual Cash Flow Aytu BioScience

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-1.94 M -1.39 M -5.13 M -28.8 M -26 M -28.4 M -13.8 M -15.9 M -13.8 M - - - -37.7 K -37.8 K -64.8 K

Depreciation & Amortization

5.38 M 6.72 M 8.82 M 10.1 M 9.2 M 5.71 M 2.73 M 2.59 M 4.36 M 875 K 118 K 97.5 K 58.4 K 53.4 K 6.76 K

Accounts Payables

10.6 M 10.3 M 13.5 M - - 11.8 M 2.3 M 2.12 M 2.22 M - - - 6.84 K 5.84 K -

Accounts Receivables

31.2 M 23.5 M 28.9 M 21.7 M 28.2 M 5.18 M 1.74 M 579 K 528 K 162 K 157 K - - - -

Total Inventories

11.4 M 12.1 M 12 M 10.8 M 16.3 M 10 M 1.44 M 1.34 M 1.31 M 525 K 39.4 K - - - -

All numbers in USD currency

Quarterly Cash Flow Aytu BioScience

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -618 K - - - -1.19 M - - - -211 K - - - -9.15 M -11.6 M - - -3.79 M -12.6 M 19.7 M - -7.98 M -10.9 M -7.97 M - -2.99 M -9.09 M -2.99 M - -2.74 M -7.05 M -2.74 M - -4.22 M - - - - - - - - - - -9.33 K - -15.2 K - -6.86 K -32.5 K -17.2 K -6.86 K -8.92 K -25.3 K -19.4 K -8.92 K -11 K -55.5 K -38 K -11 K

Depreciation & Amortization

100 K 803 K - 100 K 100 K 1.33 M - 200 K 300 K 924 K - 1.84 M 1.85 M 2.3 M 4.5 M 500 K 400 K 2.68 M 5.35 M 68 K 18 K 2.04 M 4.01 M 2.09 M 16 K 869 K 2.16 M 869 K 16 K 557 K 1.23 M 557 K 329 K 653 K 1.32 M 653 K 26 K 822 K 1.72 M 822 K 12 K 129 K 242 K 129 K 1.2 K 24.6 K 2.39 K - 1.2 K 3.75 K 2.53 K 1.2 K 1.29 K 4.79 K 3.32 K 1.29 K 1.66 K 5.1 K 3.36 K 1.66 K

Accounts Payables

14.3 M 12.3 M 10.6 M 12 M 11.7 M 13.5 M 10.3 M 10.5 M 10.5 M - 13.5 M - - - - - - - 19.3 M 16.5 M 7.16 M 5.77 M 11.8 M 11.8 M 9.6 M 2.63 M 2.3 M 2.3 M 2.37 M 2.11 M 2.37 M 2.12 M 3.41 M 1.66 M 2.22 M 2.22 M - 2.32 M 2.32 M - - - - 546 K 3.58 K 310 650 K 310 12.8 K 6.84 K 6.84 K 6.84 K 12 K 5.84 K 5.84 K 5.84 K 5.46 K 330 330 330

Accounts Receivables

30.9 M 33.2 M 31.2 M 35.8 M 25.4 M 23.2 M 23.5 M 29.9 M 29.4 M 29.9 M 28.9 M 34 M 25.5 M 27.9 M 21.7 M 27.6 M 23 M 21.6 M 28.2 M 28.2 M 7 M 6.11 M 5.63 M 5.18 M 5.2 M 1.71 M 1.74 M 1.74 M 1.48 M 760 K 1.48 M 579 K 1.38 M 1.21 M 528 K 528 K 582 K 509 K 162 K 162 K 288 K 168 K 157 K 157 K - - - - - - - - - - - - - - - -

Total Inventories

8.66 M 10.1 M 11.4 M 11.1 M 11.1 M 11.7 M 12.1 M 13.2 M 13 M 13 M 12 M 13.6 M 13 M 12.9 M 10.8 M 13.9 M 16.6 M 16.3 M 16.3 M 16.3 M 6.57 M 11.5 M 10 M 10 M 2.49 M 1.38 M 1.44 M 1.44 M 1.64 M 1.31 M 1.64 M 1.34 M 1.38 M 1.17 M 1.31 M 1.31 M 439 K 585 K 525 K 525 K 653 K 494 K 39.4 K 39.4 K - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Aytu BioScience, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.64 -1.89 % $ 1.09 B canadaCanada
ADMA Biologics ADMA Biologics
ADMA
$ 16.45 0.43 % $ 3.92 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 76.75 0.85 % $ 1.48 B usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 19.93 -1.14 % $ 2.51 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.83 4.23 % $ 4.53 M chinaChina
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.4 -1.81 % $ 1.39 B britainBritain
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 163.82 -0.14 % $ 8.15 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 66.98 3.8 % $ 12.8 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.88 2.51 % $ 908 M israelIsrael
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.75 3.79 % $ 11.7 B usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Cabaletta Bio Cabaletta Bio
CABA
$ 3.41 4.77 % $ 3.98 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 25.71 -0.5 % $ 688 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Codexis Codexis
CDXS
$ 1.1 12.24 % $ 80.7 M usaUSA
Certara Certara
CERT
$ 7.33 1.24 % $ 1.18 B usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA